{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:33:53Z","timestamp":1790627633141,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105067","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:23:49Z","timestamp":1764721429000},"page":"105067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Antibody-Drug Conjugates in urothelial, prostate, and renal cell cancers: A review of current and emerging therapies"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2985-4980","authenticated-orcid":false,"given":"Anne","family":"Perera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Hettiarachchige Don","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Maniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105067_bib1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO-24-01989","article-title":"Phase I, first-in-human study of FOR46 (FG-3246), an immune-modulating antibody-drug conjugate targeting CD46, in patients with metastatic castration-resistant prostate cancer","volume":"43","author":"Aggarwal","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib2","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO-24-01989","article-title":"Phase I, first-in-human study of FOR46 (FG-3246), an immune-modulating antibody-drug conjugate targeting CD46, in patients with metastatic castration-resistant prostate cancer","volume":"43","author":"Aggarwal","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib3","unstructured":"Amgen and CuraGen, n.d. Anti-TIM-1-vcMMAE | CDX-014 [WWW Document]. \u3008https:\/\/www.adcreview.com\/celldex-therapeutics-cdx-014\/\u3009 (Accessed 20 October 2025)."},{"key":"10.1016\/j.critrevonc.2025.105067_bib4","unstructured":"AstraZeneca, 2025. Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA). National Library of Medicine."},{"key":"10.1016\/j.critrevonc.2025.105067_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/LCTT.S307324","article-title":"Spotlight on trastuzumab deruxtecan (DS-8201,T-DXd) for HER2 mutation positive non-small cell lung cancer","volume":"12","author":"Azar","year":"2021","journal-title":"Lung Cancer Targets Therapy"},{"key":"10.1016\/j.critrevonc.2025.105067_bib6","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib7","unstructured":"Klaassen, Z., 2024. BL-B01D1-201: BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma [WWW Document]. ESMO 2024. \u3008https:\/\/www.urotoday.com\/conference-highlights\/esmo-2024\/esmo-2024-bladder-cancer\/154751-esmo-2024-bl-b01d1-201-bl-b01d1-an-egfr-x-her3-bispecific-antibody-drug-conjugate-in-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma.html\u3009 (Accessed 11 August 2025)."},{"key":"10.1016\/j.critrevonc.2025.105067_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113379","article-title":"Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response","volume":"195","author":"Bosi","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105067_bib9","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody\u2013drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105067_bib10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105067_bib11","unstructured":"Daiichi Sankyo Inc, AstraZeneca Pharmaceuticals LP, n.d. ENHERTU - HIGHLIGHTS OF PRESCRIBING INFORMATION [WWW Document]. Reference ID: 5518598. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761139s032s035lbl.pdf\u3009 (Accessed 20 October 2025)."},{"key":"10.1016\/j.critrevonc.2025.105067_bib12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1\u20132 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib13","doi-asserted-by":"crossref","first-page":"S744","DOI":"10.1016\/j.annonc.2022.07.582","article-title":"453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I\/II study","volume":"33","author":"Doi","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib14","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.clgc.2015.10.002","article-title":"Sacituzumab govitecan, a novel antibody\u2013drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma","volume":"14","author":"Faltas","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105067_bib15","unstructured":"FDA, 2024a. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer [WWW Document]. FDA."},{"key":"10.1016\/j.critrevonc.2025.105067_bib16","unstructured":"FDA, 2024b. FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer [WWW Document]. FDA. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer\u3009 (Accessed 20 October 2025)."},{"key":"10.1016\/j.critrevonc.2025.105067_bib17","unstructured":"FDA, 2024c. FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors [WWW Document]. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-enhertu-fam-trastuzumab-deruxtecan-nxki-unresectable-or\u3009 (Accessed 20 October 2025)."},{"key":"10.1016\/j.critrevonc.2025.105067_bib18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody\u2013drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2025.105067_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.438","article-title":"Primary analysis from DS8201-A-U105: a phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC)","volume":"40","author":"Galsky","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib21","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO.2007.15.0532","article-title":"Phase I trial of the prostate-specific membrane antigen\u2013directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer","volume":"26","author":"Galsky","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib22","doi-asserted-by":"crossref","first-page":"S1138","DOI":"10.1016\/j.annonc.2024.08.2052","article-title":"1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la\/mUC): RC48G001 cohort C","volume":"35","author":"Galsky","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib23","unstructured":"Gilead Sciences, Inc., 2024. Gilead Provides Update on Phase 3 TROPiCS-04 Study [WWW Document]."},{"key":"10.1016\/j.critrevonc.2025.105067_bib24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody\u2013drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.105067_bib25","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.105067_bib26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib27","unstructured":"Guo Hongqian, 2021. A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer. ID:NCT05016973."},{"key":"10.1016\/j.critrevonc.2025.105067_bib28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/ajco.14001","article-title":"Systemic treatment of advanced and metastatic urothelial cancer: the landscape in Australia","volume":"19","author":"Gurney","year":"2023","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib31","unstructured":"Hu Hailong, 2024. Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable. ID: NCT05495724."},{"key":"10.1016\/j.critrevonc.2025.105067_bib32","unstructured":"IRCCS San Raffaele, 2025. Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer. National Library of Medicine.."},{"key":"10.1016\/j.critrevonc.2025.105067_bib33","unstructured":"Jason Harris, 2024. Disitamab Vedotin Shows Efficacy in HER2-Negative Metastatic Urothelial Carcinoma [WWW Document]."},{"key":"10.1016\/j.critrevonc.2025.105067_bib34","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/01.ju.0000158121.49085.ba","article-title":"CD70: a new tumor specific biomarker for renal cell carcinoma","volume":"173","author":"Junker","year":"2005","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib35","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105067_bib36","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/onco.13628","article-title":"A randomized phase II study of AGS-16C3F versus axitinib in previously treated patients with metastatic renal cell carcinoma","volume":"26","author":"Kollmannsberger","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.105067_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1240864","article-title":"Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews","volume":"13","author":"Leaning","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib39","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","article-title":"Sacituzumab govitecan demonstrates efficacy across tumor Trop-2 expression levels in patients with advanced urothelial cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105067_bib40","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s10637-020-00945-y","article-title":"Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma","volume":"38","author":"McGregor","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.critrevonc.2025.105067_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The double antibody drug conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib42","unstructured":"John Shen, 2024. APEX-01: First-in-Human Phase 1\/2 Study of ARX517, an Anti-PSMA ADC, in Patients with mCRPC [WWW Document]. ESMO 2023."},{"key":"10.1016\/j.critrevonc.2025.105067_bib43","unstructured":"Merck Sharp & Dohme LLC\u200b\u200b\u200b\u200b\u200b\u200b, 2025a. A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +\/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B\/KEYMAKER-U04) [WWW Document]. ClinicalTrials.gov. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05845814?term=NCT05845814&rank=1\u3009. (Accessed 21 October 2025)."},{"key":"10.1016\/j.critrevonc.2025.105067_bib44","unstructured":"Merck Sharp & Dohme LLC, 2025b. Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15\/ KEYNOTE-B15\/EV-304) (KEYNOTE-B15). National Library of Medicine."},{"key":"10.1016\/j.critrevonc.2025.105067_bib45","unstructured":"Merck Sharp & Dohme LLC, 2025c. Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905\/KEYNOTE-905\/EV-303). National Library of Medicine."},{"key":"10.1016\/j.critrevonc.2025.105067_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and SAfety of Trastuzumab Deruxtecan in Patients With HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib47","first-page":"530.e15","article-title":"Phase 1\/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer","volume":"34","author":"Milowsky","year":"2016","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.critrevonc.2025.105067_bib48","unstructured":"National Cancer Institute, n.d. Anti-CD70 antibody-drug conjugate SGN-CD70A [WWW Document]. NCI Drug Dictionary. \u3008https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/anti-cd70-antibody-drug-conjugate-sgn-cd70a\u3009 (Accessed 20 October 2025a)."},{"key":"10.1016\/j.critrevonc.2025.105067_bib49","unstructured":"National Cancer Institute, n.d. anti-CD70 antibody-drug conjugate MDX-1203 [WWW Document]. NCI Drug Dictionary. \u3008https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/anti-cd70-antibody-ddrug-conjugate-mdx-1203\u3009 (Accessed 20 October 2025b)."},{"key":"10.1016\/j.critrevonc.2025.105067_bib50","unstructured":"National Cancer Institute, n.d. anti-ENPP3 antibody-drug conjugate AGS-16C3F [WWW Document]. NCI Drug Dictionary. \u3008https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/anti-enpp3-antibody-drug-conjugate-ags-16c3f\u3009 (Accessed 20 October 2025c)."},{"key":"10.1016\/j.critrevonc.2025.105067_bib51","unstructured":"National Center for Biotechnology Information, n.d. Tisotumab Vedotin [WWW Document]. PubChem Compound Summary for Tisotumab Vedotin. \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tisotumab-Vedotin\u3009 (Accessed 20 October 2025)."},{"key":"10.1016\/j.critrevonc.2025.105067_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.105067_bib53","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1021\/acs.molpharmaceut.9b00326","article-title":"Pharmacokinetics and biodistribution of a [ 89 Zr]Zr-DFO-MSTP2109A anti-STEAP1 antibody in metastatic castration-resistant prostate cancer patients","volume":"16","author":"O\u2019Donoghue","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105067_bib54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-015-2909-2","article-title":"First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70","volume":"77","author":"Owonikoko","year":"2016","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105067_bib55","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/cncr.31912","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma","volume":"125","author":"Pal","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.105067_bib56","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.23.01720","article-title":"TROPHY-U-01 cohort 2: a phase II study of sacituzumab govitecan in cisplatin-ineligible patients with metastatic urothelial cancer progressing after previous checkpoint inhibitor therapy","volume":"42","author":"Petrylak","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pros.23922","article-title":"PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and\/or enzalutamide: efficacy and safety in open-label single-arm phase 2 study","volume":"80","author":"Petrylak","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2025.105067_bib58","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib59","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.105067_bib60","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.105067_bib61","doi-asserted-by":"crossref","first-page":"S1137","DOI":"10.1016\/j.annonc.2024.08.2051","article-title":"1966MO EV-302: exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib62","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.semcancer.2019.12.024","article-title":"Antibody\u2013drug conjugates for lung cancer in the era of personalized oncology","volume":"69","author":"Ricciuti","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib63","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/ijms22041551","article-title":"Treating prostate cancer by antibody\u2013drug conjugates","volume":"22","author":"Rosellini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105067_bib64","doi-asserted-by":"crossref","first-page":"S1441","DOI":"10.1016\/j.annonc.2022.08.079","article-title":"LBA73 study EV-103 cohort K: antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"33","author":"Rosenberg","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib65","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib66","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib67","unstructured":"Russ Conroy, 2024. FDA Gives Fast Track Designation to ARX517 in Metastatic CRPC [WWW Document]."},{"key":"10.1016\/j.critrevonc.2025.105067_bib68","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody\u2013drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105067_bib69","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/jpm13091339","article-title":"Antibody\u2013drug conjugates for the treatment of renal cancer: a scoping review on current evidence and clinical perspectives","volume":"13","author":"Sganga","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.critrevonc.2025.105067_bib70","unstructured":"Shenderov Eugene, Mallesara Girish, Wysocki Piotr, Xu Wen, Ramlau Rodryg, Weickhardt Andrew, Zolnierek Jakub, Spira Alexander, Joshua Anthony M., Powderly John, Antonarakis Emmanuel S., Jang Sekwon, Aragon-Ching Jeanny, Shen John, Paller Channing, Vogelzang Nicholas, Leu Kirsten, Cort\u00e9s Javier, Bohac Chet, Lugowska Iwona, 2024. MGC018, an Anti-B7-H3 Antibody-Drug Conjugate (ADC), in Patients With Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion [WWW Document]."},{"key":"10.1016\/j.critrevonc.2025.105067_bib71","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2\u2013positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib72","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4568","article-title":"Preliminary efficacy and safety results from RC48-C017: a phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4566","article-title":"Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b\/2 study","volume":"41","author":"Sheng","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib74","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.critrevonc.2025.105067_bib75","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.105067_bib76","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.105067_bib77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11523-022-00872-3","article-title":"Antibody\u2013drug conjugates in uro-oncology","volume":"17","author":"Sigorski","year":"2022","journal-title":"Target Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib78","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105067_bib79","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1535-7163.MCT-23-0927","article-title":"Preclinical characterization of ARX517, a site-specific stable PSMA-targeted antibody\u2013drug conjugate for the treatment of metastatic castration-resistant prostate cancer","volume":"23","author":"Skidmore","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105067_bib80","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105067_bib81","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib82","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2025.105067_bib83","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.6_suppl.368","article-title":"SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma","volume":"31","author":"Thompson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105067_bib84","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-18-0481","article-title":"Phase I trials of anti-ENPP3 antibody\u2013drug conjugates in advanced refractory renal cell carcinomas","volume":"24","author":"Thompson","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105067_bib85","unstructured":"University of Washington, 2025. Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer. National Library of Medicine."},{"key":"10.1016\/j.critrevonc.2025.105067_bib86","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1158\/1535-7163.MCT-21-0554","article-title":"DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody\u2013drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.105067_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104874","article-title":"302MO phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic breast cancer (BC)","volume":"10","author":"Zhang","year":"2025","journal-title":"ESMO Open"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282500455X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282500455X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:38:50Z","timestamp":1770035930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282500455X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":87,"alternative-id":["S104084282500455X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105067","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-Drug Conjugates in urothelial, prostate, and renal cell cancers: A review of current and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105067"}}